Immix Biopharma, Inc.
IMMX
$10.97
$0.050.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.19M | 15.81M | 13.70M | 12.14M | 12.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.82M | 36.08M | 29.96M | 24.05M | 23.78M |
| Operating Income | -41.82M | -36.08M | -29.96M | -24.05M | -23.78M |
| Income Before Tax | -39.88M | -34.95M | -29.40M | -23.53M | -23.09M |
| Income Tax Expenses | 33.30K | 27.90K | 37.70K | 37.20K | 40.60K |
| Earnings from Continuing Operations | -39.92 | -34.98 | -29.44 | -23.56 | -23.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 0.00 | 0.00 |
| Net Income | -39.92M | -34.98M | -29.44M | -23.56M | -23.13M |
| EBIT | -41.82M | -36.08M | -29.96M | -24.05M | -23.78M |
| EBITDA | -41.48M | -35.78M | -29.71M | -23.84M | -23.66M |
| EPS Basic | -0.87 | -0.91 | -0.88 | -0.77 | -0.78 |
| Normalized Basic EPS | -0.54 | -0.57 | -0.55 | -0.48 | -0.49 |
| EPS Diluted | -0.87 | -0.91 | -0.88 | -0.77 | -0.78 |
| Normalized Diluted EPS | -0.54 | -0.57 | -0.55 | -0.48 | -0.49 |
| Average Basic Shares Outstanding | 191.29M | 157.50M | 131.84M | 121.18M | 118.67M |
| Average Diluted Shares Outstanding | 191.29M | 157.50M | 131.84M | 121.18M | 118.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |